BiotechTube

REC-1245

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unresectable

Conditions

Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas

Trial Timeline

Nov 21, 2024 → Oct 30, 2028

NCT ID
NCT06678659

About REC-1245

REC-1245 is a phase 1/2 stage product being developed by Recursion Pharmaceuticals for Unresectable. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06678659. Target conditions include Unresectable, Locally Advanced, Metastatic Cancers.

What happened to similar drugs?

1 of 20 similar drugs in Unresectable were approved

Approved (1) Terminated (1) Active (18)
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
🔄Durvalumab + Tremelimumab + Cisplatin + Gemcitabine + Carboplatin + GemcitabineAstraZenecaPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06678659Phase 1/2Recruiting

Competing Products

20 competing products in Unresectable

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
LenvatinibEisaiPhase 2
35
LenvatinibEisaiPhase 1
29
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
42
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
40
HRS-6209 in Combination with Fulvestrant + HRS-6209 in Combination with HRS-1358 + HRS-6209 in Combination with Letrozole + HRS-6209 in Combination with HRS-8080 + HRS-6209 in Combination with HRS-1358Jiangsu Hengrui MedicinePhase 1/2
39
Camrelizumab + HAIC + TKIJiangsu Hengrui MedicinePhase 2
31
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
44
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + OxaliplatinAbbViePhase 2
42